pubmed.ncbi.nlm.nih.gov

Prospects for the Use of Cannabinoids in Psychiatric Disorders - PubMed

  • ️Fri Jan 01 2021

Review

Prospects for the Use of Cannabinoids in Psychiatric Disorders

Michał Graczyk et al. Front Psychiatry. 2021.

Abstract

Increasing evidence suggests an essential role of the endocannabinoid system in modulating cognitive abilities, mood, stress, and sleep. The psychoactive effects of cannabis are described as euphoric, calming, anxiolytic, and sleep-inducing and positively affect the mood, but can also adversely affect therapy. The responses to cannabinoid medications depend on the patient's endocannabinoid system activity, the proportion of phytocannabinoids, the terpenoid composition, and the dose used. There is some evidence for a therapeutic use of phytocannabinoids in psychiatric conditions. THC and CBD may have opposing effects on anxiety. Current guidelines recommend caution in using THC in patients with anxiety or mood disorders. In a small number of clinical trials, cannabinoids used to treat cancer, HIV, multiple sclerosis, hepatitis C, Crohn's disease, and chronic neuropathic pain report decreases in anxiety or depression symptoms and presented sedative and anxiolytic effects. Several studies have investigated the influence of potential genetic factors on psychosis and schizophrenia development after cannabis use. THC may increase the risk of psychosis, especially in young patients with an immature central nervous system. There is limited evidence from clinical trials that cannabinoids are effective therapy for sleep disorders associated with concomitant conditions. There is evidence for a possible role of cannabis as a substitute for alcohol and drugs, also in the context of the risks of opioid use (e.g., opioid-related mortality). In this narrative review of the recent evidence, we discuss the prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders. However, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking. Furthermore, some disorders may be worsened by cannabis use.

Keywords: anxiety; cannabinoids; cannabis; dementia; depression; psychiatric disorders; sleep disorders; substitution therapy.

Copyright © 2021 Graczyk, Łukowicz and Dzierzanowski.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Galanter M, Kleber HD, Brady KT. The American Psychiatric Publishing Textbook of Substance Abuse Treatment, DSM-5 Edit. Arlington, VA: American Psychiatric Publishing. (2014). 10.1176/appi.books.9781615370030 - DOI
    1. Dzierzanowski T. Prospects for the use of cannabinoids in oncology and palliative care practice: a review of the evidence. Cancers. (2019) 11:129. 10.3390/cancers11020129 - DOI - PMC - PubMed
    1. Snelders S, Kaplan C, Pieters T. On cannabis, chloral hydrate, and career cycles of psychotrophic drugs in medicine. Bull Hist Med. (2006) 80:95–114. 10.1353/bhm.2006.0041 - DOI - PubMed
    1. Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, et al. . Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. (1992) 258:1946–9. 10.1126/science.1470919 - DOI - PubMed
    1. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. (2008) 20:10–4. 10.1111/j.1365-2826.2008.01671.x - DOI - PubMed

Publication types

LinkOut - more resources